The global adeno associated virus vector manufacturing market size is expected to reach USD 3.95 billion by 2030, registering a CAGR of 22.5% over the forecast period. This growth is attributed to the increasing prevalence of chronic diseases like cancers, cystic fibrosis, Duchenne muscular dystrophy, retinitis pigmentosa, and many more. AAV vector plays a vital role in the treatment of these diseases. AAV vectors also have a wide range of applications in gene therapy delivery. Companies are engaged in collaborations, mergers, and partnerships for innovative product launches with advancements in R&D.
For instance, in December 2021, Astellas and Dyno Therapeutics entered into a strategic collaboration to develop an NGS-based AAV vector for gene therapy by using Dyno’s CapsidMap platform for cardiac and skeletal muscle. Such initiatives are expected to expand their market presence in the development and production of antibodies, which is likely to support the growth of the market. The COVID-19 pandemic had a positive impact on the industry. As adeno associated virus has vast applications in vaccine manufacturing, various companies were involved in the race to manufacture the vaccine to treat COVID-19. This resulted in a sudden spur in the demand for manufacturing these vectors.
For instance, in September 2021, CEVEC and UCB entered into a strategic agreement for the use of ELEVECTA AAV vector manufacturing technology for R&D and gene therapy applications. As gene therapy involves alterations or modifications in the set of genes, it has raised many ethical issues. As a result, the U.S. government restricted the usage of federal funds for research on germline gene therapy in people. Gene therapy can help save future generations of a family from acquiring a particular genetic disorder. However, it is anticipated to affect the fetus’s development significantly. The high demand for vaccines, gene therapeutics, CGMP drugs, and products to treat & cure acute diseases and the demand for improving patient care also propel the industry growth. Thus, global stakeholders are investing significantly in expanding their production capacities to fulfill the growing demands.
For instance, in December 2021, Astellas and Dyno Therapeutics entered into a strategic collaboration to develop an NGS-based AAV vector for gene therapy by using Dyno’s CapsidMap platform for cardiac and skeletal muscle. Such initiatives are expected to expand their market presence in the development and production of antibodies, which is likely to support the growth of the market. The COVID-19 pandemic had a positive impact on the industry. As adeno associated virus has vast applications in vaccine manufacturing, various companies were involved in the race to manufacture the vaccine to treat COVID-19. This resulted in a sudden spur in the demand for manufacturing these vectors.
For instance, in September 2021, CEVEC and UCB entered into a strategic agreement for the use of ELEVECTA AAV vector manufacturing technology for R&D and gene therapy applications. As gene therapy involves alterations or modifications in the set of genes, it has raised many ethical issues. As a result, the U.S. government restricted the usage of federal funds for research on germline gene therapy in people. Gene therapy can help save future generations of a family from acquiring a particular genetic disorder. However, it is anticipated to affect the fetus’s development significantly. The high demand for vaccines, gene therapeutics, CGMP drugs, and products to treat & cure acute diseases and the demand for improving patient care also propel the industry growth. Thus, global stakeholders are investing significantly in expanding their production capacities to fulfill the growing demands.
Adeno Associated Virus Vector Manufacturing Market Report Highlights
- By the scale of operations, the commercial segment dominated the industry in 2022. Owing to the increasing R&D investment by companies and demand from vaccine manufacturers
- The neurological diseases therapeutic areasegment captured the largest share in 2022 due to the high prevalence of chronic neurodegenerative diseases and the effectiveness of the adeno associated virus vector-based therapies to treat these disease
- Vaccine is considered a key application segment, which held the largest revenue share in 2022 and is likely to remain dominant throughout the forecast period due to the rising demand for vaccine therapeutics and increasing investments & funds for the production of vaccines
- North America has established a strong regional position. The increasing incidence of cancer and high R&D expenditure is encouraging companies in the region to undertake product development, which drives the regional market
Table of Contents
Chapter 1. Methodology and Scope1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Technological advancements in manufacturing vectors
3.4.2. Robust pipelines for gene therapies and vaccines
3.4.3. Increasing number of emerging players
3.5. Market Restraint Analysis
3.5.1. Regulatory, scientific and ethical challenges
3.5.2. Production capacity challenges
3.6. Penetration and Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Scale Of Operations Business Analysis
4.1. Adeno Associated Virus Vector Manufacturing Market: Scale Of Operations Movement Analysis
4.2. Clinical
4.2.1. Clinical Market, 2018 - 2030 (USD Million)
4.3. Preclinical
4.3.1. Preclinical Market, 2018 - 2030 (USD Million)
4.4. Commercial
4.4.1. Commercial Market, 2018 - 2030 (USD Million)
Chapter 5. Method Business Analysis
5.1. Adeno Associated Virus Vector Manufacturing Market: Method Movement Analysis
5.2. In Vitro
5.2.1. In vitro Market, 2018 - 2030 (USD Million)
5.3. In Vivo
5.3.1. In vivo Market, 2018 - 2030 (USD Million)
Chapter 6. Therapeutic Area Business Analysis
6.1. Adeno Associated Virus Vector Manufacturing Market: Therapeutic Area Movement Analysis
6.2. Hematological Diseases
6.2.1. Hematological Diseases Market, 2018 - 2030 (USD Million)
6.3. Infectious Diseases
6.3.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
6.4. Genetic Disorders
6.4.1. Genetic Disorders Market, 2018 - 2030 (USD Million)
6.5. Neurological Disorders
6.5.1. Neurological Disorders Market, 2018 - 2030 (USD Million)
6.6. Ophthalmic Disorders
6.6.1. Ophthalmic Disorders Market, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Orders Market, 2018 - 2030 (USD Million)
Chapter 7. Application Business Analysis
7.1. Adeno Associated Virus Vector Manufacturing Market: Application Movement Analysis
7.2. Cell Therapy
7.2.1. Cell Therapy Market, 2018 - 2030 (USD Million)
7.3. Gene Therapy
7.3.1. Gene Therapy Market, 2018 - 2030 (USD Million)
7.4. CRO
7.4.1. CRO Market, 2018 - 2030 (USD Million)
7.5. Vaccine
7.5.1. Vaccine Market, 2018 - 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Adeno Associated Virus Vector Manufacturing Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. SWOT Analysis
8.2.2. North America adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. U.S. adeno associated virus vector manufacturing market, 2018 - 2030 (USD MILLION)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Canada adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. SWOT Analysis
8.3.2. Europe adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Germany adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.3.4. U.K.
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. U.K. adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. France adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.3.6. Italy
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Italy adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.3.7. Spain
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Spain adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Denmark adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Sweden adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Norway adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. SWOT Analysis
8.4.2. Asia Pacific adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Japan adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. China adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. India adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. South Korea adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Australia adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. Thailand adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. SWOT Analysis
8.5.2. Latin America adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Brazil adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Mexico adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Argentina adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. South Africa adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Saudi Arabia adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. UAE adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Competitive Scenario
8.6.6.4. Regulatory Framework
8.6.6.5. Kuwait adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.1.1. Roche
9.1.2. Biomarin Pharmaceutical
9.1.3. Oxford BioMedica
9.1.4. WuXi AppTec
9.1.5. YPOSKESI
9.1.6. Sarepta Therapeutics
9.1.7. Pfizer
9.1.8. Audentes Therapeutics
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Adeno associated virus vector manufacturing market Share Analysis, 2022
9.3.3. Strategy Mapping
9.3.3.1. Expansion
9.3.3.2. Acquisition
9.3.3.3. Collaborations
9.3.3.4. Product/Therapeutic Area Launch
9.3.3.5. Partnerships
9.3.3.6. Others
List of Tables
Table 1. List of Secondary Sources
TABLE 2. List of Abbreviations
TABLE 3. Global adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 4. Global adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 5. Global adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 6. Global adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 7. Global adeno associated virus vector manufacturing market, by Region, 2018 - 2030 (USD Million)
TABLE 8. North America adeno associated virus vector manufacturing market, by Country, 2018 - 2030 (USD Million)
TABLE 9. North America adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 10. North America adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 11. North America adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 12. North America adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 13. U.S. adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 14. U.S. adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 15. U.S. adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 16. U.S. adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 17. Canada adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 18. Canada adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 19. Canada adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 20. Canada adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 21. Europe adeno associated virus vector manufacturing market, by Country, 2018 - 2030 (USD Million)
TABLE 22. Europe adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 23. Europe adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 24. Europe adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 25. Europe adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 26. U.K. adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 27. U.K. adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 28. U.K. adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 29. U.K. adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 30. Germany adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 31. Germany adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 32. Germany adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 33. Germany adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 34. France adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 35. France adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 36. France adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 37. France adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 38. Italy adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 39. Italy adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 40. Italy adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 41. Italy adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 42. Spain adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 43. Spain adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 44. Spain adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 45. Spain adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 46. Denmark adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 47. Denmark adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 48. Denmark adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 49. Denmark adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 50. Sweden adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 51. Sweden adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 52. Sweden adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 53. Sweden adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 54. Norway adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 55. Norway adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 56. Norway adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 57. Norway adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 58. Asia Pacific adeno associated virus vector manufacturing market, by Country, 2018 - 2030 (USD Million)
TABLE 59. Asia Pacific adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 60. Asia Pacific adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 61. Asia Pacific adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 62. Asia Pacific adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 63. Japan adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 64. Japan adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 65. Japan adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 66. Japan adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 67. China adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 68. China adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 69. China adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 70. China adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 71. India adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 72. India adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 73. India adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 74. India adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 75. Australia adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 76. Australia adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 77. Australia adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 78. Australia adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 79. Thailand adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 80. Thailand adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 81. Thailand adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 82. Thailand adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 83. South Korea adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 84. South Korea adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 85. South Korea adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 86. South Korea adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 87. Latin America adeno associated virus vector manufacturing market, by Country, 2018 - 2030 (USD Million)
TABLE 88. Latin America adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 89. Latin America adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 90. Latin America adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 91. Latin America adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 92. Brazil adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 93. Brazil adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 94. Brazil adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 95. Brazil adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 96. Mexico adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 97. Mexico adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 98. Mexico adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 99. Mexico adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 100. Argentina adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 101. Argentina adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 102. Argentina adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 103. Argentina adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 104. Middle East and Africa adeno associated virus vector manufacturing market, by Country, 2018 - 2030 (USD Million)
TABLE 105. Middle East and Africa adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 106. Middle East and Africa adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 107. Middle East and Africa adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 108. Middle East and Africa adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 109. South Africa adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 110. South Africa adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 111. South Africa adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 112. South Africa adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 113. Saudi Arabia adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 114. Saudi Arabia adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 115. Saudi Arabia adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 116. Saudi Arabia adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 117. UAE adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 118. UAE adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 119. UAE adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 120. UAE adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
TABLE 121. Kuwait adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
TABLE 122. Kuwait adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
TABLE 123. Kuwait adeno associated virus vector manufacturing market, by Application, 2018 - 2030 (USD Million)
TABLE 124. Kuwait adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain - Based Sizing & Forecasting
FIG. 6 Market Formulation & Validation
FIG. 7 Adeno associated virus vector manufacturing market Segmentation
FIG. 8 Market Snapshot, 2022
FIG. 9 Market Trends & Outlook
FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 12 Market Challenge Relevance Analysis (Current & Future Impact)
FIG. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Market Penetration Vs Growth Prospect Mapping, 2022
FIG. 16 Global Adeno associated virus vector manufacturing market: Mode Movement Analysis
FIG. 17 Global adeno associated virus vector manufacturing market, for in vitro, 2018 - 2030 (USD Million)
FIG. 18 Global adeno associated virus vector manufacturing market, for in vivo, 2018 - 2030 (USD Million)
FIG. 19 Global Adeno associated virus vector manufacturing market: Scale Of Operations Movement Analysis
FIG. 20 Global adeno associated virus vector manufacturing market, for Clinical, 2018 - 2030 (USD Million)
FIG. 21 Global adeno associated virus vector manufacturing market, for Preclinical, 2018 - 2030 (USD Million)
FIG. 22 Global adeno associated virus vector manufacturing market, for Commercial, 2018 - 2030 (USD Million)
FIG. 23 Global Adeno associated virus vector manufacturing market: Therapeutic Area Movement Analysis
FIG. 24 Global adeno associated virus vector manufacturing market, for Hematological Diseases, 2018 - 2030 (USD Million)
FIG. 25 Global adeno associated virus vector manufacturing market, for Infectious Diseases, 2018 - 2030 (USD Million)
FIG. 26 Global adeno associated virus vector manufacturing market, for Genetic Disorders, 2018 - 2030 (USD Million)
FIG. 27 Global adeno associated virus vector manufacturing market, for Neurological Disorders, 2018 - 2030 (USD Million)
FIG. 28 Global adeno associated virus vector manufacturing market, for Ophthalmic Disorders, 2018 - 2030 (USD Million)
FIG. 29 Global adeno associated virus vector manufacturing market, for Others, 2018 - 2030 (USD Million)
FIG. 30 Global Adeno associated virus vector manufacturing market: Application Movement Analysis
FIG. 31 Global adeno associated virus vector manufacturing market, for Cell Therapy, 2018 - 2030 (USD Million)
FIG. 32 Global adeno associated virus vector manufacturing market, for Gene Therapy, 2018 - 2030 (USD Million)
FIG. 33 Global adeno associated virus vector manufacturing market, for Vaccine, 2018 - 2030 (USD Million)
FIG. 34 Regional Marketplace: Key Takeaways
FIG. 35 Regional Outlook, 2022 & 2030
FIG. 36 Global Adeno associated virus vector manufacturing market: Region Movement Analysis
FIG. 37 North America adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 38 U.S. adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 39 Canada adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 40 Europe adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 41 Germany adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 42 U.K. adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 43 France adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 44 Italy adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 45 Spain adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 46 Denmark adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 47 Sweden adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 48 Norway adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 49 Asia Pacific adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 50 Japan adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 51 China adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 52 India adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 53 Australia adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 54 South Korea adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 55 Thailand adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 56 Latin America adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 57 Brazil adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 58 Mexico adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 59 Argentina adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 60 Middle East and Africa adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 61 South Africa adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 62 Saudi Arabia adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 63 UAE adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
FIG. 64 Kuwait adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
Companies Mentioned
- Roche
- Biomarin Pharmaceutical
- Oxford BioMedica
- WuXi AppTec
- YPOSKESI
- Sarepta Therapeutics
- Pfizer
- Audentes Therapeutics
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 767.7 Million |
| Forecasted Market Value ( USD | $ 3950 Million |
| Compound Annual Growth Rate | 22.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
